Evidence map›Paper›PMID 31055966›Full record

ArticleThe American journal of psychiatry2019

Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.

Kenneth S Kendler, Henrik Ohlsson, Jan Sundquist, Kristina Sundquist

Open access · greenAbstract read
In one paragraph

Article in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.The British journal of psychiatry : the journal of mental science · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kenneth S KendlerThe Virginia Institute for Psychiatric and Behavioral Genetics and the Department of Psychiatry, Virginia Commonwealth University, Richmond (Kendler); the Center for Primary Health Care Research, Lund University, Malmö, Sweden (Ohlsson, J. Sundquist, K. Sundquist); the Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York (J. Sundquist, K. Sundquist); the Center for Community-Based Health Care Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Japan (J. Sundquist, K. Sundquist).
Henrik OhlssonThe Virginia Institute for Psychiatric and Behavioral Genetics and the Department of Psychiatry, Virginia Commonwealth University, Richmond (Kendler); the Center for Primary Health Care Research, Lund University, Malmö, Sweden (Ohlsson, J. Sundquist, K. Sundquist); the Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York (J. Sundquist, K. Sundquist); the Center for Community-Based Health Care Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Japan (J. Sundquist, K. Sundquist).
Jan SundquistThe Virginia Institute for Psychiatric and Behavioral Genetics and the Department of Psychiatry, Virginia Commonwealth University, Richmond (Kendler); the Center for Primary Health Care Research, Lund University, Malmö, Sweden (Ohlsson, J. Sundquist, K. Sundquist); the Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York (J. Sundquist, K. Sundquist); the Center for Community-Based Health Care Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Japan (J. Sundquist, K. Sundquist).
Kristina SundquistThe Virginia Institute for Psychiatric and Behavioral Genetics and the Department of Psychiatry, Virginia Commonwealth University, Richmond (Kendler); the Center for Primary Health Care Research, Lund University, Malmö, Sweden (Ohlsson, J. Sundquist, K. Sundquist); the Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York (J. Sundquist, K. Sundquist); the Center for Community-Based Health Care Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Japan (J. Sundquist, K. Sundquist).
Banner Sun Health Research Institute · US

Funding

Genetic, Social, and Developmental Epidemiology of Drug Use DisordersR01DA030005 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI KENNETH SEEDMAN KENDLER, JAN O SUNDQUIST · 2010 to 2026
$7.6M
Social, Developmental and Genetic Epidemiology of Alcohol Use DisordersR01AA023534 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI KENDLER, KENNETH SEEDMAN, SUNDQUIST, KRISTINA · 2015 to 2023
$4.0M
NIAAA NIH HHS R01 AA023534NIDA NIH HHS R01 DA030005
6 · The paper itself

Abstract

objectiveThe objective of this study was to clarify the etiology of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample.

methodsIndividuals with a registration of substance-induced psychotic disorder between 1997 and 2015 in national medical registries (N=7,606) were followed up for a mean of 84 months. Data from medical, criminal, and pharmacy registries on first-degree through third-degree relatives were used to calculate familial risk scores for nonaffective psychosis, drug abuse, and alcohol use disorder.

resultsIndividuals with substance-induced psychotic disorder had large elevations in standardized familial risk scores for drug abuse (+1.09, 95% CI=1.02, 1.15) and alcohol use disorder (+0.98, 95% CI=0.93, 1.03) and modest elevations for nonaffective psychosis (+0.35, 95% CI=0.30, 0.41). The cumulative risk for progression to schizophrenia was 11.3%; it was lowest for alcohol-induced and highest for cannabis-induced psychotic disorder, and it was predicted by early age at diagnosis of substance-induced psychotic disorder, male sex, and further registrations for episodes of drug abuse, alcohol use disorder, and substance-induced psychotic disorder. A risk prediction model found that 47% of individuals who converted to schizophrenia were in the upper 20% of risk. Familial risk scores for drug abuse and alcohol use disorder did not significantly discriminate those who converted to schizophrenia from those who did not, while familial risk score for nonaffective psychosis did (0.67, 95% CI=0.40, 0.95, versus 0.33, 95% CI=0.28, 0.39). Familial risk scores for nonaffective psychosis were indistinguishable between individuals with schizophrenia with and without prior substance-induced psychosis. Assignment of early retirement by the Swedish Social Insurance Agency strongly discriminated between individuals with substance-induced psychotic disorder with and without later schizophrenia.

conclusionsSubstance-induced psychotic disorder appears to result from substantial drug exposure in individuals at high familial risk for substance abuse and moderately elevated familial risk for psychosis. Familial risk for psychosis, but not substance abuse, predicts progression from substance-induced psychosis to schizophrenia. Schizophrenia following substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome predominantly caused by drug exposure.

Indexed as

AdultAge FactorsAlcoholismDisease ProgressionFemaleHumansMalePsychoses, Substance-InducedRegistriesRisk FactorsSchizophreniaSex FactorsSubstance-Related DisordersSwedenPsychoses-Substance-InducedSchizophrenia

Identifiers

PMID31055966
PMCPMC6718312
OpenAlexW2943577253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.